Amgen documents lawsuit against Regeneron.

.. Amgen documents lawsuit against Regeneron, Sanofi to prevent infringing manufacture of alirocumab Amgen today announced that it filed a lawsuit in the United States , and Regeneron Pharmaceuticals, Inc. for patent infringement of U.S. Patent Numbers 8,563,698, 8,829,165, and 8,859,741. These patents, which are owned by Amgen, describe and state monoclonal antibodies to proprotein convertase subtilisin/kexin type 9 . By its complaint, Amgen seeks an injunction to prevent the infringing manufacture, use and sale of Sanofi and Regeneron's alirocumab, a monoclonal antibody targeting PCSK9. Sanofi and Regeneron recently announced they have completed Phase 3 medical trials on alirocumab and plan to pursue regulatory acceptance to market alirocumab in the U.S.From a medical perspective, patients have observed sustained and early improvements that suggest profound utility. I am very happy to hear of the latest CE Mark acceptance and excited to serve as a TITAN II investigator and further donate to the clinical experience. .. Blue Assistance selects Accenture to greatly help support medical health insurance assistance providers business in Italy Blue Assistance, a subsidiary of Reale Mutua Assicurazioni Group the biggest Italian mutual insurer, offers decided on Accenture to supply back office and It all services in a multi-year agreement made to help support and expand its medical health insurance assistance providers business in Italy. Accenture provides development also, execution and ongoing maintenance solutions for Blue Assistance's It all applications that support these procedures.

Related Articles

Other Articles from "allergy":